Doc Gumshoe's June 2023 Short Takes
15 Comments Read MoreArticles
Alzheimer’s Disease, RSV, Migraines and more…
March 2023 Miscellany
Following Up on Your Suggestions – September 2022
Updates on Alzheimer's Disease, Anti-Inflammatories, Prostate Cancer, Vitamin D and more...
20 Comments Read MoreDe-teasing the “Takeover Target for May” pitched by Dylan Jovine
March 2022 Bulletins — Brief, but Relevant
Doc Gumshoe looks at infections, weight-loss drugs, cataracts and dementia, Vitamin D supplements and more...
23 Comments Read MoreCOVID-19: What Now?
Most of this Doc Gumshoe posting was ready to go a couple of days before Thanksgiving. But then, you know what happened: the new variant (now named Omicron) surfaced in South Africa. So I finished up another Doc Gumshoe epistle that I had been working on and quickly got it to Travis so I could […]
70 Comments Read MoreResponses to Questions and Comments: August 2021
I was hoping to keep COVID-19 out of this piece, but new things keep flooding in, and I can’t totally ignore them. However, I’ll save them to the end of the story. They are both “good news,” more or less, and I like to leave you with a bit of cheer, when possible. Sleep and […]
37 Comments Read MoreFriday File: Cheaper SPACs and a Year to Remember
A few buys in the Real Money Portfolio, plus check-ins on safer SPAC prices, quarters from BOMN and CHWY, and much more...
27 Comments Read More“#1 Micro-Cap Stock for February” teased — what’s up with this “1,000% gains starting February 22” pitch from Behind the Markets?
Another Look at the Current Migraine Scene
Thinking about COVID-19 almost gives me a migraine, or at least a heavy and achy sensation in my noggin – perhaps not an actual migraine, thankfully, but threatening and unpleasant all the same. Happily, thinking about migraines will not give me COVID-19. But migraines are by no means a topic of no consequence, […]
13 Comments Read MoreCombating Cancer: The Current Battle Plan
Ten Major Threats to Global Health According to the World Health Organization
Doc Gumshoe looks at pollution, vaccination, and the WHO's priorities and plans
37 Comments Read MoreCancer: The Lay of the Land in 2018
Putting the name of this imperious disease in the title of my homily places a weighty responsibility on me. Who am I to attempt to put forth relevant information and sensible opinions on this topic, the mere mention of which makes most normal folk distinctly uneasy? But I probably pay more attention to […]
34 Comments Read MoreLate Summer Pickings: September 2018
Doc Gumshoe on Coffee vs. Energy Drinks, Opioid Tapering, Smallpox, Vaccinations, Lyme Disease, HIV and more...
26 Comments Read MoreMigraine Update
Is Aurinia’s Supremacy in Lupus Nephritis Threatened by Glaxo’s Benlysta?
Glenn Newberry in an earlier post today was asking whether Benlysta from GlaxoSmithKline (GSK), being trialled for lupus nephritis, poses any threat to Aurinia (AUPH). Benlysta is a monoclonal antibody that binds to and inhibits BAFF (B-cell activating factor). A company called Anthera (ANTH) is trialling blisibimod, an oral agent that does the same thing. […]
432 Comments Read MoreAlzheimer’s Wrap-Up
Abiding Ambiguity: Achaogen and Arrowhead
[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. He choses his own topics, and his words and opinions are his own. He has agreed to our trading restrictions. Enjoy!] In his smoky baritone, singer Stuart Staples of British midlands musical act Tindersticks is bemoaning how he suspects the woman he […]
151 Comments Read MoreDoc Gumshoe’s Perspectives on the Current State of Healthcare: The Long View
[Ed Note: Michael Jorrin, who I like to call “Doc Gumshoe”, is a longtime medical writer (not a doctor) who shares his thoughts with us from time to time, generally on non-financial topics in health and medicine (as today, though, he sometimes mentions a couple publicly traded companies). His words and opinions are his own. […]
17 Comments Read MoreThe Great Gallic Foie Gras Hack
Cancer Care: Where Are We and Where Are We Headed?
[ed note: Michael Jorrin is a longtime medical writer (not a doctor) who covers health and medical topics and trends for our readers, generally without an investment thesis. His words are his own, enjoy!] In the Doc Gumshoe blog about cancer that appeared in June of 2013 (you can check it out here), I commented […]
36 Comments Read MoreBiotech Dim Sum: ARTH, CLDN, ESPR, BLRX, GILD and a New Baby Biotech for 2015
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. His previous columns can be found here. Enjoy!] Every New Year, a friend and I flew to Boston. She’d gone to medical school […]
544 Comments Read MoreThe Finale is Grand: The Gain from Pain Mainly Explained
Ebola, Vaccination, Flu, Viral Transmission: The Links and the Kinks
Ebola: To Parse, Perchance to Parlay
Yellow Eyes, White Powders, and an Unknown Nordic Biotech That May Green Things Up for Investors
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own. Enjoy!] In the Saturday morning Looney Tunes many of us saw as children, one trope always stuck with me: that of the grand piano falling from way up high and crashing, splintering itself. There’s a […]
1,033 Comments Read MoreHepatitis with a C
Antibiotics Don’t Get No Respect, But You Can Still Profit From Them
What’s Happening in Cancer Treatment? Are We Making Progress, or Are We Stuck?
Today we’re sharing another piece from our medical contributor, “Doc Gumshoe” — we have added the stock tickers to the companies he mentions for your researching convenience, but this survey of the state of cancer research — which will hopefully be good background help to folks trying to understand the basic science behind pitches for […]
57 Comments Read MoreWe use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
The stock to BUY is GlaxoSmithKline plc, (GSK) and the stock to AVOID is Affirm (AFRM). It's the same video from several...
I can confirm the bullish pick of GSK as of 12,31,2022. Bearish on AFRM.. That's after 80+ minutes on the video. $49...
FWIW: Here's background on FULC's only Phase 1-2 trial in progress: "Fulcrum acquired rights to losmapimod from GlaxoSmi...
$GILD $GSK #HIV - Barrons just published an article on this subject, quoting a Piper Jaffray's analyst who mildly refute...
Was this what the Dr. was forseeing? Introducing PfizerKline: Analyst Makes New Case for Merger of GlaxoSmithKline (GSK...
Team, Anyone have this company in watch-list, Glenn ? http://www.oxfordbiomedica.co.uk/ Pipeline is very impressive ...
This company Agenus (AGEN) could be a target of GlaxoSmithKline (GSK) after this news today with this phase 3 shingles v...
Clovis Oncology ($CLVS) is teaming up with GlaxoSmithKline ($GSK) in a new non-small cell lung cancer trial targeting EG...
True, there are always expensive companies, but that's 20X estimated earnings for 2017, 30 months into the future. BMY ...
RE: GILD First-Line Combination of Ambrisentan and Tadalafil Reduces Risk of Clinical Failure Compared to Monotherapy i...